Efficacy of Docetaxel and Oxaliplatin Regimen as a Second-Line Therapy for Patients with Advanced Pancreatic Adenocarcinoma.
Adenocarcinoma
/ drug therapy
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Docetaxel
/ administration & dosage
Female
Follow-Up Studies
Humans
Liver Neoplasms
/ drug therapy
Lymphatic Metastasis
Male
Middle Aged
Oxaliplatin
/ administration & dosage
Pancreatic Neoplasms
/ drug therapy
Prospective Studies
Survival Rate
Treatment Outcome
Advanced cancer pancreas
Docetaxel
Oxaliplatin
Survival
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
pubmed:
26
5
2018
medline:
23
1
2020
entrez:
26
5
2018
Statut:
ppublish
Résumé
Pancreatic cancer is the deadliest of the 21 most common cancers, largely because it is often identified at a late stage, we aimed to determine the control rates, and PFS for patients who received docetaxel-oxaliplatin regimen as a 2nd line therapy. Twenty-five patients with advanced cancer pancreas progressed or failed on 1st line treatments and justified the inclusion criteria were eligible to receive Docetaxel 75 mg/m No patients achieved complete response (CR), and the control rate (control rate = partial response (PR = 6/25, 24%) + stable disease (SD = 9/25, 36%) was 60% while disease progression (DP) was demonstrated in (10/25) 40% of patients, the median PFS was 7 ± 0.777 ms (95% confidence interval: 5.467-8.524 ms), grade 3 neutropenia, fatigue, diarrhea, and vomiting were developed in 12%, 8%, 12% and 8% of patients respectively. Docetaxel-oxaliplatin regimen was an active regimen in advanced cancer pancreas based on our encouraging results without occurrence of grade four toxicities.
Sections du résumé
BACKGROUND AND AIM OF WORK
OBJECTIVE
Pancreatic cancer is the deadliest of the 21 most common cancers, largely because it is often identified at a late stage, we aimed to determine the control rates, and PFS for patients who received docetaxel-oxaliplatin regimen as a 2nd line therapy.
PATIENTS AND METHODS
METHODS
Twenty-five patients with advanced cancer pancreas progressed or failed on 1st line treatments and justified the inclusion criteria were eligible to receive Docetaxel 75 mg/m
RESULTS
RESULTS
No patients achieved complete response (CR), and the control rate (control rate = partial response (PR = 6/25, 24%) + stable disease (SD = 9/25, 36%) was 60% while disease progression (DP) was demonstrated in (10/25) 40% of patients, the median PFS was 7 ± 0.777 ms (95% confidence interval: 5.467-8.524 ms), grade 3 neutropenia, fatigue, diarrhea, and vomiting were developed in 12%, 8%, 12% and 8% of patients respectively.
CONCLUSIONS
CONCLUSIONS
Docetaxel-oxaliplatin regimen was an active regimen in advanced cancer pancreas based on our encouraging results without occurrence of grade four toxicities.
Identifiants
pubmed: 29797144
doi: 10.1007/s12029-018-0116-1
pii: 10.1007/s12029-018-0116-1
doi:
Substances chimiques
Oxaliplatin
04ZR38536J
Docetaxel
15H5577CQD
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
519-524Références
J Clin Oncol. 2010 Apr 1;28(10):1645-51
pubmed: 20194854
Anticancer Res. 2010 Jul;30(7):2905-9
pubmed: 20683031
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Eur J Cancer. 2011 Jul;47(11):1676-81
pubmed: 21565490
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
J Clin Oncol. 2014 Aug 10;32(23):2423-9
pubmed: 24982456
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
BMC Cancer. 2016 Jan 15;16:21
pubmed: 26772812